|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
CTD_human |
Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population.
|
30718926 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population.
|
30718926 |
2019 |
|
Body Weight
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Meta-analysis identifies common variants associated with body mass index in east Asians.
|
22344219 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
The seroprevalence of anti-GP2 IgA was markedly higher than that of IgG in patients with CD in contrast to previous studies.
|
30465525 |
2019 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Pancreatic secretory granule membrane major glycoprotein 2, whose autoantibodies are a known biomarker of Crohn's disease, was also immunoprecipitated from IBD patient serum, as an additional internal positive control.
|
31249498 |
2019 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
The novel anti-GP2<sub>1</sub> and GP2<sub>4</sub> antibodies are associated with Crohn's disease of the pouch in ulcerative colitis patients after IPAA.
|
30411391 |
2018 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Pancreatic secretory zymogen-granule membrane glycoprotein 2 (GP2) has been identified as a major autoantigenic target in Crohn's disease patients.
|
29635104 |
2018 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Glycoprotein 2[GP2] is a specific target of pancreatic autoantibodies[PAbs] in Crohn's disease(CD) and is involved in gut innate immunity processes.
|
29321484 |
2018 |
|
Crohn Disease
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We tested serum anti-zymogen granule glycoprotein 2 (GP2) antibodies, including its novel isoform alpha, for association with genetic variants, diagnosis, disease stratification, and prediction of CD courses in a combined cross-sectional and cohort study.
|
27753692 |
2016 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Both anti-GP2 (P < 0.001) and anti-CUZD1 (P < 0.001) were significantly more prevalent in patients with Crohn's disease than in ulcerative colitis.
|
26273818 |
2015 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Anti-GP2 IgG and IgA constitute novel CD specific autoantibodies, the quantification of which could improve the serological diagnosis of IBD.
|
21195704 |
2011 |
|
Crohn Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
PAB-positive sera from patients with Crohn's disease (n = 42) displayed significantly higher IgG reactivity to rat GP2 in ELISA than either PAB-negative sera (n = 31), or sera from patients with ulcerative colitis (n = 49), or sera from blood donors (n = 69) (p<0.0001, respectively).
|
19549613 |
2009 |
|
Inflammatory Bowel Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Autoantibodies to four GP2 isoforms (aGP2<sub>1-4</sub>) were found in patients with inflammatory bowel diseases but reactivity against specific GP2 epitopes has not been investigated in PSC yet.
|
30233574 |
2018 |
|
Inflammatory Bowel Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
This set of specific binders will enable the development of suitable diagnostic tools for GP2-related studies in IBD.
|
29635104 |
2018 |
|
Inflammatory Bowel Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
|
28691939 |
2017 |
|
Inflammatory Bowel Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Patients with IBD (224 patients with Crohn's disease and 136 patients with ulcerative colitis), who were tested for anti-GP2 and anti-CUZD1 immunoglobulin G and immunoglobulin A by indirect immunofluorescence on transfected cells between 2005 and 2013, were included.
|
26273818 |
2015 |
|
Inflammatory Bowel Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Anti-GP2 IgG and IgA constitute novel CD specific autoantibodies, the quantification of which could improve the serological diagnosis of IBD.
|
21195704 |
2011 |
|
Inflammatory Bowel Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Anti-GP2 autoantibodies constitute novel Crohn's disease-specific markers, the quantification of which could significantly improve the serological diagnosis of IBD.
|
19549613 |
2009 |
|
Ulcerative Colitis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Anti-GP2 IgA and IgG levels were higher in patients with CD (25%) than in those with UC (5%) and controls (2%).
|
30465525 |
2019 |
|
Ulcerative Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Both anti-GP2 (P < 0.001) and anti-CUZD1 (P < 0.001) were significantly more prevalent in patients with Crohn's disease than in ulcerative colitis.
|
26273818 |
2015 |
|
Ulcerative Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
CD patients displayed significantly higher reactivity to GP2 than UC patients and BD (p<0.0001), respectively.
|
21195704 |
2011 |
|
Ulcerative Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
PAB-positive sera from patients with Crohn's disease (n = 42) displayed significantly higher IgG reactivity to rat GP2 in ELISA than either PAB-negative sera (n = 31), or sera from patients with ulcerative colitis (n = 49), or sera from blood donors (n = 69) (p<0.0001, respectively).
|
19549613 |
2009 |
|
Primary sclerosing cholangitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Recently, new biomarkers such as antibodies to glycoprotein 2 have been found to be associated with an increased risk of developing CCA in PSC.
|
31463807 |
2020 |
|
Hemorrhagic Fever, Ebola
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ebola GP2 plays a critical role in virus entry and has similarities in mechanism and structure to the HIV gp41 protein for which inhibitors have been successfully developed.
|
31092576 |
2019 |